Unlikely. I think it's more to do with this: Synthon will host a call to discuss data from its EU comparative trial for its generic Copaxone on Mar.27 [via MS]
MNTA—It’s doubtful that someone has a mole at the US Supreme Court who knows whether cert will be granted for Teva’s application. On the merits, cert would seem to be unlikely insofar as this case has no big issues for the US healthcare system as a whole (in contrast to the Lovenox patent case, which does).
Market Data 
Markets 
AI
